P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.
Pierre Peterlin,Jacques Delaunay,Thierry Guillaume,Thomas Gastinne,Beatrice Mahe,Viviane Dubruille,Nicolas Blin,Amandine Le Bourgeois,Eolia Brissot,Laurence Lodé,Steven Le Gouill,Philippe Moreau,Mohamad Mohty,Patrice Chevallier +13 more
TL;DR: Full CD3(+) TCC was independently associated with a lower risk of relapse in adults receiving a dUCB TCF RIC allogeneic transplantation, and the need to develop immunotherapy approaches allowing for early conversion to full chimerism after this type of transplantation is highlighted.
Journal ArticleDOI
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma
Hartmut Goldschmidt,Meletios A. Dimopoulos,S. Vincent Rajkumar,Katja Weisel,Philippe Moreau,Wee Joo Chng,Wee Joo Chng,Gabor Mikala,Michele Cavo,Karthik Ramasamy,Kaveri Suryanarayan,Zhaoyang Teng,Richard Labotka,Maria-Victoria Mateos +13 more
TL;DR: These analyses demonstrate the significantly higher rate of deepening responses with ixazomib versus placebo maintenance and the association between deepening response and prolonged PFS.
Journal ArticleDOI
Ancestim (r-metHuSCF) plus filgrastim and/or chemotherapy for mobilization of blood progenitors in 513 poorly mobilizing cancer patients: the French compassionate experience.
Valérie Lapierre,JF Rossi,F Heshmati,Nabih Azar,A Vekhof,C Makowski,Philippe Moreau,Denis Caillot,A Auperin,Christian Chabannon +9 more
TL;DR: It is concluded that a combination of ancestim with filgrastim successfully mobilized CD34+ cells in peripheral blood, and allowed adequate collection in preparation for autologous transplantation in approximately one-third of poorly mobilizing patients.
Journal ArticleDOI
Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients
Pierre Peterlin,Christophe Leux,Thomas Gastinne,Virginie Roland,Beatrice Mahe,Viviane Dubruille,Jacques Delaunay,Patrice Chevallier,Thierry Guillaume,Nicolas Blin,Sameh Ayari,Aline Clavert,Mohamad Mohty,Christelle Dousset,Noel Milpied,Jean Luc Harousseau,Philippe Moreau,Soraya Wuilleme,Anne Moreau,Steven Le Gouill +19 more
TL;DR: It is shown that transplant patients with MCL remain highly exposed to relapse, and the absence of TBI in conditioning regimen modifies neither PFS nor OS.
Journal ArticleDOI
Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma
Cyrille Touzeau,Nicolas Blin,Aline Clavert,Virginie Roland,Marion Loirat,Benoit Tessoulin,Steven Le Gouill,Lucie Planche,Martine Pennetier,Beatrice Mahe,Mohamad Mohty,Florent Malard,Pierre Peterlin,Viviane Dubruille,Philippe Moreau +14 more
TL;DR: The overall response rate was 62% and the median progression-free survival was 14 months, which compares favorably to that described in the two pivotal prospective studies that formed the basis for the approval of Len/Dex in the relapse setting.